Trikafta 100-50-75 MG/75MG PKT 14S
Ended Awarded Last action
- Contract number
- SPE2DR26FCZE7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,332
Award facts
- Contract value 100% obligated
- $19,331.61 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $19,331.61 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Trikafta 100-50-75 mg/75 mg packets (14-count). The delivery order, issued on January 9, 2026, with an ultimate completion date of January 12, 2026, was made without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group is performing at the Park Ridge, Illinois location and represents a critical pharmaceutical supplier within the Department of Defense's medical supply chain.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion regional prime vendor contract awarded in November 2025 and extending through December 31, 2036. The PPV-G GEN V program is part of a broader $30.3 billion acquisition strategy designed to provide firm fixed-price delivery orders for pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare facilities worldwide. This delivery order for Trikafta, a cystic fibrosis treatment medication, exemplifies the diverse pharmaceutical requirements fulfilled under this strategic contract vehicle.
Quick answers
Who was awarded contract SPE2DR26FCZE7?
SPE2DR26FCZE7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 9, 2026.
How much is contract SPE2DR26FCZE7 worth?
The government has obligated $19,332 on SPE2DR26FCZE7.
Is contract SPE2DR26FCZE7 an order under another contract?
Yes. SPE2DR26FCZE7 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZE7 competed?
The extent of competition for SPE2DR26FCZE7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award